Celgene's need for speed behind $500m antibody alliance with Sutro
This article was originally published in Scrip
Sutro Biopharma hopes to announce one or two more collaborations with Big Pharma or large biotech companies within the next 12 months that will be similar to the San Francisco-based company's $500 million-plus deal with Celgene to design and develop novel antibody-drug conjugates (ADCs) and bi-specific antibodies for two undisclosed targets, and to manufacture an antibody from Celgene's early-stage pipeline.
You may also be interested in...
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.